Follow-The-Filings

Security

ARTV

Artiva Biotherapeutics Inc. · COM

Equity holders as of 2026 Q1 (each manager’s latest book)

5 owners 1 new 1 exit max 0.0% (Vanguard Group Inc.)

grid → activity →
owners 5
max % 0.0%
tracked value $3M
qoq N 1 A 1 R 2 E 1

holders

sorted by % of portfolio · long equity only · exits show last held size

manager % port activity shares value history
Vanguard Group Inc. 2025 Q4 stale 0.0% Add 0.00 pp 246,006 $1M hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% Reduce 0.00 pp 123,270 $794 hist
Two Sigma Investments, LP 2025 Q4 stale 0.0% Exit 0.00 pp 144,864 $621 hist
Renaissance Technologies LLC 2026 Q1 0.0% Reduce 0.00 pp 80,038 $515 hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% New 0.0% 15,870 $102 hist
Marshall Wace - Marshall Wace, LLP exited 2026 Q1 last 2025 Q4 0.0% Exit 0.00 pp 79,559 $341 hist

5 current · 1 exited last period · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2024 FY2025
Revenue — —
Gross profit — —
Gross margin — —
Net income -$65.37M -$83.86M
Net margin — —

Balance sheet

Metric FY2024 FY2025
Total current assets $188.63M $112.67M
Total non-current assets * $20.95M $18.27M
Total assets $209.58M $130.94M
Total current liabilities $12.25M $13.09M
Total non-current liabilities * $10.69M $7.88M
Total equity $186.64M $109.97M

Cash flow

Metric FY2024 FY2025
Cash from operations -$55.03M -$76.75M
Cash from investing -$120.46M $63.41M
Cash from financing $162.23M $9,000
Net change in cash -$13.27M -$13.33M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders